DelMar Pharmaceuticals Presents Phase I/II GBM Clinical Trial Data and Outlines Future Clinical Development Plans at ASCO 2016 Annual Meeting June 6, 2016 • 8:00 AM EDT
DelMar Pharmaceuticals Announces Successful Completion of End-of-Phase 2 Meeting with FDA on VAL-083 for the Treatment of Refractory Glioblastoma Multiforme May 25, 2016 • 8:00 AM EDT
DelMar Pharmaceuticals Announces Reverse Stock Split in Preparation for Proposed Senior Exchange Uplisting May 19, 2016 • 10:16 AM EDT
DelMar Pharmaceuticals Announces Third Quarter Fiscal Year 2016 Financial Results and Corporate Update May 13, 2016 • 8:00 AM EDT
DelMar Pharmaceuticals, Inc. Announces $5.6 Million Private Placement Of Preferred Shares May 5, 2016 • 8:00 AM EDT
DelMar Pharmaceuticals Updates Ongoing Phase I/II Refractory GBM Clinical Trial with VAL-083 at American Association Cancer Research (AACR) Annual Meeting April 19, 2016 • 9:10 AM EDT
DelMar Pharmaceuticals Announces New Data Supporting the Unique Anti-cancer Mechanism of VAL-083 April 19, 2016 • 9:00 AM EDT
DelMar's VAL-083 Demonstrates Promise in the Treatment of Non-Small Cell Lung Cancer and Ovarian Cancer April 18, 2016 • 9:00 AM EDT